Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose

Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose

Abstract Background Heart failure (HF), the leading cause of morbidity and mortality in the US, affects 6.6 million adults with an estimated additional 3 million people by 2030. More than 50% of HF patients have heart failure with preserved left ventricular ejection fraction (HFpEF). These patients...

Descripció completa

Dades bibliogràfiques
Autors principals: Janet D. Pierce, Diane E. Mahoney, John B. Hiebert, Amanda R. Thimmesch, Francisco J. Diaz, Carol Smith, Qiuhua Shen, Dinesh Pal Mudaranthakam, Richard L. Clancy
Format: Article
Idioma:English
Publicat: BMC 2018-04-01
Col·lecció:BMC Cardiovascular Disorders
Matèries:
Heart failure with preserved ejection fraction (HFpEF); ubiquinol
D-ribose
Bioenergetics
Accés en línia:http://link.springer.com/article/10.1186/s12872-018-0796-2

Internet

http://link.springer.com/article/10.1186/s12872-018-0796-2

Ítems similars